Compare IPCA Labs with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs NOVARTIS - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS NOVARTIS IPCA LABS/
NOVARTIS
 
P/E (TTM) x 29.9 902.4 3.3% View Chart
P/BV x 6.1 27.1 22.4% View Chart
Dividend Yield % 0.2 1.6 12.3%  

Financials

 IPCA LABS   NOVARTIS
EQUITY SHARE DATA
    IPCA LABS
Mar-19
NOVARTIS
Mar-19
IPCA LABS/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,042980 106.3%   
Low Rs590600 98.3%   
Sales per share (Unadj.) Rs298.6198.7 150.3%  
Earnings per share (Unadj.) Rs35.021.0 166.9%  
Cash flow per share (Unadj.) Rs49.422.3 222.1%  
Dividends per share (Unadj.) Rs3.0010.00 30.0%  
Dividend yield (eoy) %0.41.3 29.0%  
Book value per share (Unadj.) Rs247.1307.5 80.4%  
Shares outstanding (eoy) m126.3524.69 511.7%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.74.0 68.7%   
Avg P/E ratio x23.337.7 61.9%  
P/CF ratio (eoy) x16.535.5 46.5%  
Price / Book Value ratio x3.32.6 128.5%  
Dividend payout %8.647.7 18.0%   
Avg Mkt Cap Rs m103,10819,508 528.6%   
No. of employees `00013.40.6 2,313.6%   
Total wages/salary Rs m7,8741,171 672.4%   
Avg. sales/employee Rs Th2,807.08,445.4 33.2%   
Avg. wages/employee Rs Th585.82,015.7 29.1%   
Avg. net profit/employee Rs Th329.0891.0 36.9%   
INCOME DATA
Net Sales Rs m37,7324,907 769.0%  
Other income Rs m577783 73.7%   
Total revenues Rs m38,3095,689 673.3%   
Gross profit Rs m6,901123 5,619.5%  
Depreciation Rs m1,82432 5,736.5%   
Interest Rs m18916 1,186.8%   
Profit before tax Rs m5,465858 637.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,042340 306.6%   
Profit after tax Rs m4,422518 854.2%  
Gross profit margin %18.32.5 730.8%  
Effective tax rate %19.139.6 48.1%   
Net profit margin %11.710.6 111.1%  
BALANCE SHEET DATA
Current assets Rs m23,7788,055 295.2%   
Current liabilities Rs m10,9751,850 593.2%   
Net working cap to sales %33.9126.4 26.8%  
Current ratio x2.24.4 49.8%  
Inventory Days Days10445 230.5%  
Debtors Days Days6634 194.4%  
Net fixed assets Rs m20,368150 13,596.5%   
Share capital Rs m253123 204.8%   
"Free" reserves Rs m30,9717,469 414.7%   
Net worth Rs m31,2247,592 411.3%   
Long term debt Rs m1,4090-   
Total assets Rs m45,5079,824 463.2%  
Interest coverage x30.054.9 54.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 166.0%   
Return on assets %10.15.4 186.6%  
Return on equity %14.26.8 207.7%  
Return on capital %17.311.5 150.6%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30858 30,049.3%   
Fx outflow Rs m6,2661,326 472.5%   
Net fx Rs m11,042-1,269 -870.3%   
CASH FLOW
From Operations Rs m4,923-1,943 -253.4%  
From Investments Rs m-1,5632,742 -57.0%  
From Financial Activity Rs m-1,832-298 614.4%  
Net Cashflow Rs m1,528501 304.7%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 2.0 570.0%  
FIIs % 25.3 1.6 1,581.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 21.5 80.9%  
Shareholders   36,892 41,647 88.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Telecom Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended higher, tracking positive global sentiments.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 5, 2020 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS